Cardiol Therapeutics Inc. - Class A Common Shares (CRDL)
1.1200
-0.0100 (-0.88%)
Cardiol Therapeutics is a biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases
The company is dedicated to advancing the treatment of heart conditions by leveraging its proprietary formulations and research into the therapeutic potential of cannabidiol, a compound derived from cannabis. Through rigorous scientific investigation and clinical trials, Cardiol aims to produce effective solutions that can improve quality of life for patients suffering from various heart-related ailments, with a vision of making significant contributions to the field of cardiology.

Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.
Via MarketBeat · November 29, 2024

Via Benzinga · November 19, 2024

Cardiol Therapeutics shares are trading lower by 20% Wednesday morning. The company announced a $13.5 million public offering.
Via Benzinga · October 9, 2024

Via Benzinga · October 9, 2024

CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024

On Wednesday, 200 companies hit new 52-week lows.
Via Benzinga · October 19, 2022

During Friday's session, 198 companies made new 52-week lows.
Key Facts About Today's 52-Week Highs And Lows:
Alibaba Group Holding (NYSEBABA) is the largest...
Via Benzinga · March 11, 2022

Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Via News Direct · June 17, 2024

Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Via News Direct · May 28, 2024

CRDL stock results show that Cardiol Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 14, 2024

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Via Benzinga · May 14, 2024

CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · April 2, 2024
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies.
Via Talk Markets · January 31, 2024
Cardiol Therapeutics (NASDAQ: CRDL)
Advancements in Therapies for Inflammatory Heart Diseases
--News Direct--
Via News Direct · October 13, 2023

697,000 people die from heart disease every year in the United States – that is one in every five deaths.
Via Benzinga · October 12, 2023

On Tuesday, Cardiol Therapeutics Inc. (NASDAQCRDL) (TSX: CRDL) announced positive study results demonstrating that subcutaneously administered cannabidiol - the active pharmaceutical ingredient in Cardiol's novel CRD-38 subcutaneous (SUBQ) formulati
Via Benzinga · October 10, 2023

Gainers Near Intelligence, Inc. (NASDAQNIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer.
Via Benzinga · September 21, 2023

During Tuesday's session, 78 companies made new 52-week lows.
Via Benzinga · October 18, 2022

On Tuesday, 44 companies hit new 52-week lows.
Via Benzinga · October 4, 2022

Gainers Bright Green Corp. (NASDAQBGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to list on a major U.S. stock exchange.
Via Benzinga · May 19, 2022

The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) from Cardiol Therapeutics Inc. (NASDAQCRDL) to start a Phase 2 open-label pilot study designed to evaluate the tolerance and safety of CardiolRx, in patients with recurrent pericarditis.
Via Benzinga · May 17, 2022

Gainers
Casa Systems, Inc. (NASDAQCASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core...
Via Benzinga · April 19, 2022

Gainers
Casa Systems, Inc. (NASDAQCASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions....
Via Benzinga · April 18, 2022

Gainers
MedAvail Holdings, Inc. (NASDAQMDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of...
Via Benzinga · April 18, 2022

Upgrades
Loop Capital upgraded the previous rating for Aspen Technology Inc (NASDAQAZPN) from Hold to Buy. In the second quarter, Aspen Technology showed an EPS of $1.20,...
Via Benzinga · March 17, 2022